Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

CYPHERPUNK TECHNOLOGIES INC. Operating Cash Flow

CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Operating Cash Flow of -$6.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12

  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.69M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.43M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.62M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.32M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for fiscal 2025 was -$43.90M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for fiscal 2024 was -$60.30M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for fiscal 2023 was -$43.75M.
  • CYPHERPUNK TECHNOLOGIES INC. net cash provided by (used in) operating activities for fiscal 2022 was -$49.04M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$2.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$6.12M
10-Q · filed 2026-08-12
-$12.74M
derived: sum of 3 quarters · filed 2026-08-12
-$21.06M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$3.43M
10-Q · filed 2026-05-14
-$10.05M
derived: sum of 2 quarters · filed 2026-05-14
-$18.37M
derived: sum of 3 quarters · filed 2026-05-14
-$32.85M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$6.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$14.94M
derived: sum of 2 quarters · filed 2026-03-16
-$29.42M
derived: sum of 3 quarters · filed 2026-08-12
-$43.90M
10-K · filed 2026-03-16
2025-09-30-$8.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$22.80M
derived: sum of 2 quarters · filed 2026-08-12
-$37.28M
10-Q · filed 2025-11-12
-$52.80M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$14.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$28.97M
10-Q · filed 2026-08-12
-$44.48M
derived: sum of 3 quarters · filed 2026-08-12
-$60.08M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$14.48M
10-Q · filed 2026-05-14
-$29.99M
derived: sum of 2 quarters · filed 2026-05-14
-$45.59M
derived: sum of 3 quarters · filed 2026-05-14
-$59.26M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$15.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$31.11M
derived: sum of 2 quarters · filed 2026-03-16
-$44.78M
derived: sum of 3 quarters · filed 2026-03-16
-$60.30M
10-K · filed 2026-03-16
2024-09-30-$15.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$29.27M
derived: sum of 2 quarters · filed 2025-11-12
-$44.79M
10-Q · filed 2025-11-12
-$55.17M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$13.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$29.19M
10-Q · filed 2025-08-14
-$39.57M
derived: sum of 3 quarters · filed 2025-08-14
-$50.05M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$15.52M
10-Q · filed 2025-05-13
-$25.90M
derived: sum of 2 quarters · filed 2025-05-13
-$36.38M
derived: sum of 3 quarters · filed 2025-05-13
-$46.57M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$10.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
-$20.87M
derived: sum of 2 quarters · filed 2025-03-26
-$31.05M
derived: sum of 3 quarters · filed 2025-03-26
-$43.75M
10-K · filed 2025-03-26
2023-09-30-$10.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$20.67M
derived: sum of 2 quarters · filed 2024-11-13
-$33.37M
10-Q · filed 2024-11-13
-$46.39M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$10.19M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$22.89M
10-Q · filed 2024-08-12
-$35.90M
derived: sum of 3 quarters · filed 2024-08-12
-$48.15M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$12.70M
10-Q · filed 2024-05-13
-$25.71M
derived: sum of 2 quarters · filed 2024-05-13
-$37.97M
derived: sum of 3 quarters · filed 2024-05-13
-$50.23M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$13.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
-$25.27M
derived: sum of 2 quarters · filed 2024-03-18
-$37.53M
derived: sum of 3 quarters · filed 2024-03-18
-$49.04M
10-K · filed 2024-03-18
2022-09-30-$12.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$24.51M
derived: sum of 2 quarters · filed 2023-11-13
-$36.03M
10-Q · filed 2023-11-13
-$46.75M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$12.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$23.78M
10-Q · filed 2023-08-14
-$34.49M
derived: sum of 3 quarters · filed 2023-08-14
-$42.59M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$11.52M
10-Q · filed 2023-05-15
-$22.23M
derived: sum of 2 quarters · filed 2023-05-15
-$30.34M
derived: sum of 3 quarters · filed 2023-05-15
-$38.09M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$10.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24
-$18.82M
derived: sum of 2 quarters · filed 2023-03-24
-$26.57M
derived: sum of 3 quarters · filed 2023-03-24
-$35.16M
10-K · filed 2023-03-24
2021-09-30-$8.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$15.85M
derived: sum of 2 quarters · filed 2022-11-14
-$24.44M
10-Q · filed 2022-11-14
-$30.43M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$7.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
-$16.34M
10-Q · filed 2022-08-12
-$22.33M
derived: sum of 3 quarters · filed 2022-08-12
-$28.92M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$8.59M
10-Q · filed 2022-05-13
-$14.57M
derived: sum of 2 quarters · filed 2022-05-13
-$21.17M
derived: sum of 3 quarters · filed 2022-05-13
-$30.62M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$5.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
-$12.58M
derived: sum of 2 quarters · filed 2022-03-11
-$22.03M
derived: sum of 3 quarters · filed 2022-03-11
-$25.96M
10-K · filed 2022-03-11
2020-09-30-$6.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$16.04M
derived: sum of 2 quarters · filed 2021-11-12
-$19.97M
10-Q · filed 2021-11-12
-$25.86M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$9.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
-$13.38M
10-Q · filed 2021-08-13
-$19.27M
derived: sum of 3 quarters · filed 2021-08-13
-$26.23M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31-$3.93M
10-Q · filed 2021-05-14
-$9.82M
derived: sum of 2 quarters · filed 2021-05-14
-$16.78M
derived: sum of 3 quarters · filed 2021-05-14
-$23.96M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$5.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$12.85M
derived: sum of 2 quarters · filed 2021-03-12
-$20.03M
derived: sum of 3 quarters · filed 2021-03-12
-$26.90M
10-K · filed 2021-03-12
2019-09-30-$6.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
-$14.14M
derived: sum of 2 quarters · filed 2020-11-12
-$21.01M
10-Q · filed 2020-11-12
-$28.06M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$7.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
-$14.05M
10-Q · filed 2020-08-13
-$21.10M
derived: sum of 3 quarters · filed 2020-08-13
-$28.55M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31-$6.87M
10-Q · filed 2020-05-14
-$13.92M
derived: sum of 2 quarters · filed 2020-05-14
-$21.37M
derived: sum of 3 quarters · filed 2020-05-14
-$27.42M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31-$7.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$14.50M
derived: sum of 2 quarters · filed 2020-03-16
-$20.55M
derived: sum of 3 quarters · filed 2020-03-16
-$26.03M
10-K · filed 2020-03-16
2018-09-30-$7.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14
-$13.51M
derived: sum of 2 quarters · filed 2019-11-14
-$18.98M
10-Q · filed 2019-11-14
-$25.35M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$6.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$11.53M
10-Q · filed 2019-08-09
-$17.90M
derived: sum of 3 quarters · filed 2019-08-09
-$20.26M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$5.48M
10-Q · filed 2019-05-15
-$11.85M
derived: sum of 2 quarters · filed 2019-05-15
-$14.20M
derived: sum of 3 quarters · filed 2019-05-15
-$21.27M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$6.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
-$8.73M
derived: sum of 2 quarters · filed 2019-04-01
-$15.79M
derived: sum of 3 quarters · filed 2019-04-01
-$22.14M
10-K · filed 2019-04-01
2017-09-30-$2.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
-$9.42M
derived: sum of 2 quarters · filed 2018-11-09
-$15.77M
10-Q · filed 2018-11-09
-$23.07M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30-$7.06M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-08
-$13.41M
10-Q · filed 2018-08-08
-$20.71M
derived: sum of 3 quarters · filed 2018-08-08
-$28.08M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31-$6.35M
10-Q/A · filed 2018-08-08
-$13.65M
derived: sum of 2 quarters · filed 2018-08-08
-$21.02M
derived: sum of 3 quarters · filed 2018-08-08
2016-12-31-$7.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
-$14.67M
derived: sum of 2 quarters · filed 2018-02-23
-$25.34M
10-K · filed 2018-02-23
2016-09-30-$7.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
-$18.04M
10-Q · filed 2017-11-13
2016-06-30-$10.67M
10-Q · filed 2017-08-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06